Creyon Bio and Eli Lilly Forge Partnership to Develop RNA-Targeted Oligonucleotide Therapies
Creyon Bio and Eli Lilly Forge Partnership to Develop RNA-Targeted Oligonucleotide Therapies Creyon Bio, Inc., a leader in innovative RNA-targeted therapies, has announced a transformative global licensing and multi-target research…
Xencor Reports Positive Early Data for Anti-TL1A Antibody in Bowel Disease
Xencor Reports Positive Early Data for Anti-TL1A Antibody in Bowel Disease Xencor, Inc. a leading clinical-stage biopharmaceutical company specializing in the development of engineered antibodies for the treatment of cancer…
Sage Therapeutics Reports Q1 2025 Results and Pipeline Highlights
Sage Therapeutics Reports Q1 2025 Results and Pipeline Highlights Sage Therapeutics, Inc., a biopharmaceutical company committed to advancing brain health, released its financial results and operational highlights for the first…
QIAGEN Enhances Digital PCR Lineup With New Lentivirus Tools for Cell and Gene Therapy QC
QIAGEN Enhances Digital PCR Lineup With New Lentivirus Tools for Cell and Gene Therapy QC In a move that further cements its position as a key player in the evolving…
Guardant Health Showcases Strong Shield Test Results Across 10 Cancer Types
Guardant Health Showcases Strong Shield Test Results Across 10 Cancer Types At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Guardant Health, Inc. , a leader…
Claritas Rx Unveils Groundbreaking Care Coordination Platform for Specialty and Rare Disease Patients
Claritas Rx Unveils Groundbreaking Care Coordination Platform for Specialty and Rare Disease Patients In an era where healthcare delivery is increasingly fragmented, and specialty and rare disease patients often navigate…
Alnylam Secures Positive CHMP Recommendation for Vutrisiran in Treating ATTR Amyloidosis with Cardiomyopathy
Alnylam Secures Positive CHMP Recommendation for Vutrisiran in Treating ATTR Amyloidosis with Cardiomyopathy In a significant regulatory milestone for RNA interference (RNAi) therapeutics, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the industry…
Qualthera Health Launches R&D Subsidiary for Drug Repurposing and Novel Delivery
Qualthera Health Launches R&D Subsidiary for Drug Repurposing and Novel Delivery Qualthera Pharmaceuticals Ltd. Co. aims to reshape the future of therapeutics through a patient-driven, data-informed approach to repurposing proven…
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase…
Contineum Therapeutics Names Timothy Watkins as CMO and Head of Development
Contineum Therapeutics Names Timothy Watkins as CMO and Head of Development Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience, inflammation, and immunology (NI&I) disorders,…
IFF Pharma Solutions Set to Highlight Its Portfolio at Excipient World 2025
IFF Pharma Solutions Set to Highlight Its Portfolio at Excipient World 2025 IFF Pharma Solutions, a division of International Flavors & Fragrances Inc. and a global leader in polymer innovation,…
Prilenia and Ferrer Partner on Pridopidine Commercialization and Development in Europe
Prilenia and Ferrer Partner on Pridopidine Commercialization and Development in Europe Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for neurodegenerative diseases, announced a significant new…